As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
At the pace with which the proportion of overweight people is growing, half of Nepal’s adult population will be obese by 2050 ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
Mehmet Oz will likely face questions during his confirmation hearing about his past support of expanding the Medicare ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
A produtora do Ozempic, Novo Nordisk, planeja fabricar mais medicamentos para o mercado dos Estados Unidos localmente; a ...
1d
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
Rep. Paul Tonko (D-N.Y.) and more than 50 colleagues in Congress sent a letter to HHS Secretary Robert F. Kennedy Jr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback